Navigation Links
Major breakthrough may pave the way for therapeutic vaccines
Date:12/17/2009

It should be possible to use therapeutic vaccines to create both cheap and effective drugs for diseases like cancer and allergies. One problem in developing such vaccines has previously been the lack of adjuvants, substances that make vaccines more effective. However, there has now been a major breakthrough in this area. The study, led by scientists at Uppsala University, is published in the December issue of the journal Vaccine.

Many of the treatment methods that are developed today for allergies, cancer, and autoimmune diseases are based on the use of so-called monoclonal antibodies. The cost of these protein pharmaceuticals is high, between 15 000 and 150 000 dollars per patient and year, and long periods of treatment are often needed. Therapeutic vaccines contain no pre-produced antibodies but rather stimulate our immune system to produce its own therapeutic antibodies. They are considerably less expensive to manufacture than the drugs that are now being produced.

"Therapeutic vaccines that target the same molecules in the body as the various monoclonal antibodies would enable us to reduce the cost of treatment significantly, and also decrease the number of visits patients need to make to the clinic," says Lars Hellman, professor of molecular and comparative immunology at the Department of Cell and Molecular Biology, Uppsala University, who directed the study.

One of the biggest problems when it comes to developing therapeutic vaccines has been the lack of so-called adjuvants, immune-stimulating substances that are added to boost the effect of the vaccine. Until now, there has been only one adjuvant that is approved for use in humans, and this substance has proven to have little or no effect when the target molecule is endogenous, that is, produced by the body itself. To develop new and more potent adjuvants, researchers from Uppsala University, in collaboration with colleagues from the Shemyakin-Ovchinnikov Institute in Moscow, have performed comprehensive analyses of various potential combinations.

"We have made a very important breakthrough by managing to identify a substance that is biologically degradable and that exhibits considerably higher activity than the adjuvants that have been used in the past," says Lars Hellman.

"These new and highly promising findings are an important step toward developing more cost-effective drugs for some of our major public health diseases," he says.


'/>"/>

Contact: Lars Hellman
lars.hellman@icm.uu.se
46-018-471-4532
Uppsala University
Source:Eurekalert

Related biology news :

1. Oscar Pistorius artificial limbs give him clear, major advantage for sprint running
2. Oberthur Technologies: Major Security Certifications for the Identity Product Range
3. LSU ichthyologist lands major grant to study fish family history
4. USU scientists report major advance in human antibody therapy against deadly Nipah virus
5. NSF grant supports Rutgers-Camden program for science majors
6. A major step in making better stem cells from adult tissue
7. Major discovery opens door to leishmania treatment
8. How mitochondrial gene defects impair respiration, other major life functions
9. BioConference Live Attracts Major Life Science Sponsors
10. Restoring a natural root signal helps to fight a major corn pest
11. Family planning a major environmental impact
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/21/2016)... -- Unique technology combines v ...   Xura, Inc. (NASDAQ: ... communications services, today announced it is working alongside SpeechPro ... particularly those in the Financial Services Sector, the ability ... a mobile app, alongside, and in combination with, traditional ...
(Date:3/15/2016)... 15, 2016 Yissum Research Development Company ... company of the Hebrew University, announced today the formation ... technology of various human biological indicators. Neteera Technologies has ... from private investors. ... detection of electromagnetic emissions from sweat ducts, enables reliable ...
(Date:3/11/2016)... , March 11, 2016 ... new market research report "Image Recognition Market by Technology ... (Marketing and Advertising), by Deployment Type (On-Premises and Cloud), ... To 2022", published by MarketsandMarkets, the global market is ... to USD 29.98 Billion by 2020, at a CAGR ...
Breaking Biology News(10 mins):
(Date:5/26/2016)... (PRWEB) , ... May 26, 2016 , ... ... manufacturing company, today announced several positive developments that position the Company for the ... result of the transaction, Craig F. Kinghorn has been appointed Chairman of the ...
(Date:5/25/2016)... ... 2016 , ... Founder of the Fitzmaurice Hand Institute in ... of the hand by the National Board of Physicians and Surgeons, as of ... in his pursuit of providing the most comprehensive, effective treatment for his patients, ...
(Date:5/25/2016)... ... May 25, 2016 , ... Biohaven Pharmaceutical Holding Company Ltd. ... the company’s orphan drug designation request covering BHV-4157 for the treatment of Spinocerebellar ... FDA. , Spinocerebellar ataxia is a rare, debilitating neurodegenerative disorder that is ...
(Date:5/23/2016)... ... ... need for blood donations in South Texas and across the nation is growing. , But ... blood donations are on the decline. In fact, donations across the country are at their ... Texas in the last four years alone. , There is no substitute for blood. , ...
Breaking Biology Technology: